CoChat

Early Basal Insulin Therapy Decreases New-Onset Diabetes after Renal Transplantation

Open access
Hecking, Manfred, Haidinger, Michael, Döller, Dominik, Werzowa, Johannes, Tura, Andrea, Zhang, Jinyao, Tekoglu, Hilal, Pleiner, Johannes, Wrba, Thomas, Rasoul-Rockenschaub, Susanne, Mühlbacher, Ferdinand, Schmaldienst, Sabine, Druml, Wilfred, Hörl, Walter H., Krebs, Michael, Wolzt, Michael, Pacini, Giovanni, Port, Friedrich K., Säemann, Marcus D. · 2012 · Journal of the American Society of Nephrology
Cited by 226

The DOI matches its Crossref record; 10 of the 10 references it cites were found in a registry or an index.

Abstract

No effective interventions to reduce risk for new-onset diabetes after transplantation (NODAT), a condition associated with postoperative hyperglycemia and reduced patient and graft survival, have been established. In this 1-year, proof-of-concept clinical trial, we randomly assigned 50 renal transplant recipients to immediate-postoperative isophane insulin for evening blood glucose ≥140 mg/dl (treatment group) or short-acting insulin and/or oral antidiabetic agents for blood glucose ≥180-250 mg/dl (standard-of-care control group). We included only patients without a history of diabetes who received tacrolimus. By the third postoperative evening, all patients in the treatment group had blood glucose ≥140 mg/dl and were subsequently treated with basal insulin; during the first 3 weeks after transplantation, the mean ± SD daily insulin dosage was 17±11 IU/d. Among controls, 23 (92%) of 25 had blood glucose ≥200 mg/dl and 18 (72%) of 25 received standard-of-care antihyperglycemic treatment. Asymptomatic hypoglycemia occurred five times in the treatment group and once in the control group. Throughout follow-up, the treatment group had 73% lower odds of NODAT (odds ratio, 0.27) than the control group, and hemoglobin A1c was on average 0.38% lower in the treatment group than the control group. Twelve months after transplantation, all patients in the treatment group were insulin-independent, whereas 7 (28%) of 25 controls required antidiabetic agents. The groups did not differ for insulin sensitivity, but the treatment group showed better β-cell function throughout the 1-year follow-up. In conclusion, this study suggests regimens that include basal insulin significantly reduce the odds for NODAT after renal transplantation, presumably via insulin-mediated protection of β cells.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1681/asn.2011080835

Cites

10 of 10 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 10 references

Cited by

See all 226

Metadata

Authors
Hecking, M., Haidinger, M., Döller, D., Werzowa, J., Tura, A., Zhang, J., Tekoglu, H., Pleiner, J., Wrba, T., Rasoul-Rockenschaub, S., Mühlbacher, F., Schmaldienst, S., Druml, W., Hörl, W. H., Krebs, M., Wolzt, M., Pacini, G., Port, F. K., & Säemann, M. D.
Venue
Journal of the American Society of Nephrology
Published
2012-04
Volume
23
Issue
4
Pages
739-749
ISSN
1046-6673 (ISSN-L)
OpenAlex
W2143724469
Cited by
226
References
10
FWCI
12.04
Type
journal article
Language
en
Open access
green

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Early Basal Insulin Therapy Decreases New-Onset Diabetes after Renal Transplantation. https://app.cochat.ai/papers/10.1681/asn.2011080835
The paper
Hecking, M., Haidinger, M., Döller, D., Werzowa, J., Tura, A., Zhang, J., Tekoglu, H., Pleiner, J., Wrba, T., Rasoul-Rockenschaub, S., Mühlbacher, F., Schmaldienst, S., Druml, W., Hörl, W. H., Krebs, M., Wolzt, M., Pacini, G., Port, F. K., & Säemann, M. D. (2012). Early Basal Insulin Therapy Decreases New-Onset Diabetes after Renal Transplantation. Journal of the American Society of Nephrology. https://doi.org/10.1681/asn.2011080835

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.